FDA reviews risk-benefit profile of certain oral contraceptives

The FDA launched a safety review of birth control pills that contain drospirenone, in light of two recent studies in the British Medical Journal concluding that such products cause a higher risk of blood clots than levonorgestrel-based contraceptives. The finding conflicts with some previous studies that also compared the synthetic hormones, the agency said. The FDA is "evaluating the conflicting results from these studies and will look at all currently available information to fully assess the risks and benefits of drospirenone."

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN